Study of Q702 in Subjects with Relapsed or Refractory Chronic Graft-versus-Host Disease (cGVHD)

2025-522680-14-00 Protocol QRNT-012 Human pharmacology (Phase I) - Bioequivalence study Ongoing, recruiting

Start 23 Dec 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 10 sites · Protocol QRNT-012

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ongoing, recruiting
Participants planned 18
Countries 1
Sites 10

Chronic Graft-versus-Host Disease

Key facts

Sponsor
Qurient Co. Ltd.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
23 Dec 2025 → ongoing
Decision date (initial)
2025-11-24
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Chronic Graft-versus-Host Disease

VersionLevelCodeTermSystem organ class
27.0 PT 10066261 Chronic graft versus host disease 100000004870

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Qurient Co. Ltd.

Sponsor organisation
Qurient Co. Ltd.
Address
C Dong 801 Pdc 242 Pangyo-Ro, Bundang Bundang
City
Seongnam
Postcode
13487
Country
Korea, Republic of

Scientific contact point

Organisation
Qurient Co. Ltd.
Contact name
Head of Clinical Development

Public contact point

Organisation
Qurient Co. Ltd.
Contact name
Qurient Co., Ltd.

Locations

1 EU/EEA country · 10 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 16 10
Rest of world
United States
2

Investigational sites

Spain

10 sites · Ongoing, recruiting
Hospital Clinic De Barcelona
Hematology, Calle Villarroel 170, 08036, Barcelona
Hospital Universitario Marques De Valdecilla
Hematology, Avenida Valdecilla Sn, 39008, Santander
Clinica Universidad De Navarra
Hematology, Pio XII Etorbidea 36, 31008, Pamplona
Hospital General Universitario Gregorio Maranon
Hematology, Calle Del Doctor Esquerdo 46, 28007, Madrid
University Hospital Virgen Del Rocio S.L.
Hematology, Avenida De Manuel Siurot S/n, 41013, Sevilla
Hospital Clinico Universitario De Valencia
Hematology, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitario Puerta De Hierro De Majadahonda
Hematology, Calle De Joaquin Rodrigo 2, 28222, Majadahonda
University Clinical Hospital Virgen De La Arrixaca
Hematology, Carretera Madrid-Cartagena S/N, El Palmar, Murcia
Hospital Universitario Regional De Malaga
Hematology, Avenida De Carlos De Haya S/N, 29010, Malaga
Hospital Universitario Y Politecnico La Fe
Hematology, Avenida Fernando Abril Martorell 106, 46026, Valencia

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2025-12-23 2025-12-23

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-07-29 Spain Acceptable
2025-11-18
2025-11-24
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-12-16 Spain Acceptable
2025-11-18
2025-12-16
3 SUBSTANTIAL MODIFICATION SM-1 2025-12-17 Spain Acceptable 2026-01-19
4 NON SUBSTANTIAL MODIFICATION NSM-2 2026-02-23 Spain Acceptable 2026-02-23